Trinity Biotech Plc Financials
Trinity Biotech Plc (TRIB) reported $43.8M in revenue for fiscal year 2025, down 28.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A brief accounting profit masks a business still running on external funding as cash generation and liquidity remain weak.
In FY2025, net income turned positive at$1.9M , but operating cash flow stayed at-$5.9M and free cash flow at-$6.0M ; paired with the current ratio falling from 1.3x in FY2024 to 0.3x, that points to a profit figure lifted by non-cash items while near-term obligations became harder to cover.
The balance sheet is now creditor-dominated: total liabilities reached
Across FY2024-FY2025, the company generated negative operating cash flow in both years yet received
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Trinity Biotech Plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Trinity Biotech Plc, and counted as zero in the overall score.
Trinity Biotech Plc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Trinity Biotech Plc used $3.10 of operating cash (-$5.9M OCF vs $1.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
Trinity Biotech Plc generated $43.8M in revenue in fiscal year 2025. This represents a decrease of 28.9% from the prior year.
Trinity Biotech Plc reported $1.9M in net income in fiscal year 2025. This represents an increase of 106.1% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Trinity Biotech Plc recorded an outflow of $6.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 30.9% from the prior year.
Trinity Biotech Plc held $5.1M in cash against $20.0M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Trinity Biotech Plc's net profit margin was 4.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 55.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Trinity Biotech Plc invested $88K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 78.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
TRIB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'25 | Q1'25 | Q3'24 | Q3'23 | Q1'23 | Q3'22 | Q3'21 | Q3'20 |
|---|
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, Net Income, EPS (Diluted).
TRIB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'25 | Q1'25 | Q3'24 | Q3'23 | Q1'23 | Q3'22 | Q3'21 | Q3'20 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $103.3M+9.5% | $94.4M+58.8% | $59.4M-35.5% | $92.1M-14.0% | $107.1M-9.9% | $118.9M-8.8% | $130.4M-0.5% | $131.1M |
| Current Assets | $41.1M-10.6% | $46.0M+17.8% | $39.0M-16.3% | $46.7M-18.5% | $57.2M-21.3% | $72.7M-12.7% | $83.3M+16.7% | $71.4M |
| Cash & Equivalents | $5.2M-2.8% | $5.3M+44.1% | $3.7M-43.9% | $6.6M-37.1% | $10.5M-59.7% | $25.9M-5.2% | $27.3M+79.4% | $15.2M |
| Inventory | $19.4M-15.6% | $23.0M+15.2% | $19.9M-11.4% | $22.5M-22.7% | $29.1M0.0% | $29.1M-3.6% | $30.2M-5.6% | $32.0M |
| Accounts Receivable | $16.1M-8.0% | $17.5M+25.7% | $13.9M-11.8% | $15.8M-1.0% | $15.9M-1.3% | $16.1M-28.9% | $22.7M+8.0% | $21.0M |
| Goodwill | $51.3M+22.9% | $41.8M+156.8% | $16.3M-53.9% | $35.3M-9.0% | $38.7M+7.7% | $36.0M+6.3% | $33.9M-22.4% | $43.7M |
| Total Liabilities | $138.5M+11.9% | $123.8M+48.4% | $83.4M-11.6% | $94.3M+3.2% | $91.3M-23.4% | $119.2M-10.1% | $132.6M+5.0% | $126.4M |
| Current Liabilities | $32.1M+24.5% | $25.8M+71.4% | $15.0M-13.3% | $17.3M+24.9% | $13.9M-86.2% | $100.5M+271.4% | $27.1M+39.1% | $19.4M |
| Long-Term Debt | N/A | $10.2M-6.2% | $10.9M | N/A | $12.7M-8.2% | $13.9M+1230.6% | $1.0M0.0% | $1.0M |
| Total Equity | -$35.2M-19.7% | -$29.4M-22.8% | -$23.9M-1000.6% | -$2.2M-113.8% | $15.8M+5058.9% | -$319K+85.6% | -$2.2M-147.1% | $4.7M |
| Retained Earnings | -$79.1M-36.9% | -$57.8M-18.8% | -$48.6M-82.2% | -$26.7M-193.3% | -$9.1M-172.5% | $12.6M+18.8% | $10.6M-34.5% | $16.1M |
TRIB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'25 | Q1'25 | Q3'24 | Q3'23 | Q1'23 | Q3'22 | Q3'21 | Q3'20 |
|---|
Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
TRIB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q3'25 | Q1'25 | Q3'24 | Q3'23 | Q1'23 | Q3'22 | Q3'21 | Q3'20 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.28-0.5x | 1.78-0.8x | 2.60-0.1x | 2.69-1.4x | 4.12+3.4x | 0.72-2.4x | 3.08-0.6x | 3.67 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | 0.80 | N/A | N/A | 0.22 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, FCF Margin.
Note: Shareholder equity is negative (-$72.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.25), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Trinity Biotech Plc Ranks
Frequently Asked Questions
What is Trinity Biotech Plc's annual revenue?
Trinity Biotech Plc (TRIB) reported $43.8M in total revenue for fiscal year 2025. This represents a -28.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Trinity Biotech Plc's revenue growing?
Trinity Biotech Plc (TRIB) revenue declined by 28.9% year-over-year, from $61.6M to $43.8M in fiscal year 2025.
Is Trinity Biotech Plc profitable?
Yes, Trinity Biotech Plc (TRIB) reported a net income of $1.9M in fiscal year 2025, with a net profit margin of 4.4%.
How much debt does Trinity Biotech Plc have?
As of fiscal year 2025, Trinity Biotech Plc (TRIB) had $5.1M in cash and equivalents against $20.0M in long-term debt.
What is Trinity Biotech Plc's net profit margin?
Trinity Biotech Plc (TRIB) had a net profit margin of 4.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Trinity Biotech Plc's free cash flow?
Trinity Biotech Plc (TRIB) recorded an outflow of $6.0M in free cash flow during fiscal year 2025. This represents a -30.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Trinity Biotech Plc's operating cash flow?
Trinity Biotech Plc (TRIB) recorded an outflow of $5.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Trinity Biotech Plc's total assets?
Trinity Biotech Plc (TRIB) had $105.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Trinity Biotech Plc's capital expenditures?
Trinity Biotech Plc (TRIB) invested $88K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Trinity Biotech Plc's current ratio?
Trinity Biotech Plc (TRIB) had a current ratio of 0.25 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Trinity Biotech Plc's return on assets (ROA)?
Trinity Biotech Plc (TRIB) had a return on assets of 1.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Trinity Biotech Plc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Trinity Biotech Plc (TRIB) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.9M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Trinity Biotech Plc's debt-to-equity ratio negative or not reported?
Trinity Biotech Plc (TRIB) has negative shareholder equity of -$72.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Trinity Biotech Plc's Piotroski F-Score?
Trinity Biotech Plc (TRIB) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Trinity Biotech Plc's earnings high quality?
For every $1 of reported earnings, Trinity Biotech Plc (TRIB) used $3.10 of operating cash (-$5.9M OCF vs $1.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Trinity Biotech Plc?
Trinity Biotech Plc (TRIB) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.